Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910448 | 0.87 | ALDH1A1 (0.62) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL177519 | 0.84 | LMNA (0.80) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30098501 | 0.84 | LMNA (0.80) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13815838 | 0.83 | LMNA (0.56) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16114401 | 0.82 | LMNA (0.75) | LMNAHTTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL12736161 | 0.81 | MAPT (0.72) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9449031 | 0.81 | LMNA (0.62) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| Nitric Acid SCHEMBL9386468 | 0.81 | LMNA (0.62) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL31133173 | 0.81 | LMNA (0.61) | LMNAHTTALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3997433 | 0.80 | HSPB1 (0.63) | LMNAHTTALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| CN-113121562-A | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| EP-3719022-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| CN-101010315-A | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1993349-A | Quinazoline derivatives as ERBB receptor tyrosine kinases | ASTRAZENECA AB (SE) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-4237300-A | CHEMICAL INTERMEDIATES FOR IMIDAZO(1,2-A)PYRIDINE ANTHELMINTIC AGENTS AS WELL AS BEING A FUNGICIDE | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4177274-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4096264-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | LMNA 1242/4885HTT 4438/4885ALDH1A1 4036/4885 |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | LMNA 1242/4885HTT 4438/4885ALDH1A1 4036/4885 |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | LMNA 2964/4885HTT 3742/4885ALDH1A1 1318/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | LMNA 1078/4885HTT 4362/4885ALDH1A1 3938/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | LMNA 1242/4885HTT 4438/4885ALDH1A1 4036/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | LMNA 4384/4885HTT 2045/4885ALDH1A1 288/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | LMNA 1242/4885HTT 4438/4885ALDH1A1 4036/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | LMNA 1078/4885HTT 4362/4885ALDH1A1 3938/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | LMNA 1078/4885HTT 4362/4885ALDH1A1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.